[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"precancerous-conditions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:precancerous-conditions":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,87,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100617475","liquid-biopsy-in-early-colorectal-lesions-100617475",false,"NCT07319104","Liquid Biopsy in Early Colorectal Lesions","Biobank for Validating Liquid Biopsy in Predicting the Prognosis of Superficial Colonic Lesions","FECCO-BioBank","Inclusion Criteria:\n\n* Patient of legal age (≥ 18 years)\n* Patient with a superficial colonic tumor refered for submucosal dissection\n* Patient included in the FECCo cohort (patients will be included concomitantly in FECCO-Biobank)\n* Patient wishing to participate in the FECCO-BioBank biological collection\n\nExclusion Criteria:\n\n* Person with significant comorbidities preventing blood sampling\n* Patients with a distant metastasis detected by imaging\n* Person unable to read and write French\n* Person who have expressed their opposition to participating in this research after being informed by an investigator and having read the information sheet\n* Person not benefiting from a national health insurance scheme\n* Person under legal protection, guardianship or curatorship\n* Person participating in other study with an ongoing exclusion period","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","3 Months","OBSERVATIONAL","Early colorectal cancer screening increasingly detects small superficial colonic lesions, but current diagnostic tools still struggle to distinguish benign from malignant lesions and to assess lymph node risk. As histology after resection has limited accuracy, many patients undergo unnecessary surgery.\n\nLiquid biopsy, analyzing circulating biomarkers such as tumor DNA, extracellular vesicles, and nucleosomes, offers a non-invasive way to better classify these lesions. Emerging evidence suggests it may outperform current criteria for predicting lymph node involvement in T1 colorectal cancer.\n\nThis study will establish a biobank of 1,000 patients to identify blood-based signatures that predict tumor stage and lymph node status. The hypothesis of the study is that circulating biomarkers can accurately differentiate benign from malignant lesions and identify patients with or without lymph node metastasis.",[26,27,28],"Colorectal Neoplasms","Precancerous Conditions","Adenocarcinoma of the Colon",[30,31,32,33,34],"Lymphatic Metastasis","Endoscopy, Gastrointestinal","Liquid Biopsy","Biomarkers","Biobanking","NOT_YET_RECRUITING","2026-05-29",{"date":38,"type":39},"2026-06-02","ACTUAL",{"date":41,"type":21},"2026-06-15",{"date":43,"type":21},"2031-12-15",{"name":45,"class":46},"University Hospital, Montpellier","OTHER",12,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100605358","argon-plasma-coagulation-versus-endoscopic-mucosal-resection-for-gastric-adenoma-cler-ga-100605358","NCT07161479","Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)","A Multicenter, Randomized, Single-Blinded Trial Comparing Argon Plasma Coagulation and Endoscopic Mucosal Resection for Gastric Adenoma With Low-Grade Dysplasia","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Diagnosed with gastric adenoma with low-grade dysplasia measuring ≤ 1 cm on endoscopy\n* Scheduled to undergo endoscopic treatment\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Previous treatment for gastric adenoma or gastric cancer\n* History of gastrectomy\n* Diagnosis of gastric cancer or high-grade dysplasia at the time of enrollment\n* Presence of multiple gastric adenomas\n* Pregnant, breastfeeding, or possibility of pregnancy\n* Uncontrolled chronic illnesses that may interfere with trial participation (e.g., uncontrolled hypertension, uncontrolled diabetes, chronic kidney disease, ascites, heart failure, psychiatric disorders)","20 Years",{"count":57,"type":21},160,"INTERVENTIONAL",[60],"NA","Gastric adenomas with low-grade dysplasia (LGD) are considered precancerous lesions of the stomach. While these lesions carry a lower risk of progressing to gastric cancer compared with high-grade dysplasia, there is still uncertainty about the best way to manage them. International medical guidelines differ in their recommendations, and for very small lesions (1 cm or smaller), some guidelines provide no clear direction. This creates uncertainty for both patients and physicians about whether to treat these lesions or simply observe them over time.\n\nTwo endoscopic treatment methods are widely used in clinical practice: endoscopic mucosal resection (EMR) and argon plasma coagulation (APC). EMR involves lifting and cutting out the lesion. Its major advantage is that it removes the lesion completely and allows for detailed pathological examination. However, EMR can be technically more demanding, takes more time, and may carry higher risks of complications such as bleeding or perforation. It also usually involves higher medical costs.\n\nIn contrast, APC is a technique that uses ionized argon gas and electrical current to coagulate tissue without direct contact. APC is simpler to perform, takes less time, and is generally less invasive. Patients undergoing APC may have shorter hospital stays, lower costs, and fewer complications. However, APC does not provide a specimen for pathology, so complete removal of the lesion cannot be confirmed. This means there is a possibility of local recurrence.\n\nSeveral retrospective studies have examined APC for gastric LGD, and results have suggested it may be effective for small lesions. However, recurrence rates reported in previous studies have varied widely, from less than 2% to more than 20%. Importantly, no large randomized controlled trial has directly compared APC with EMR for small gastric LGD lesions. This study seeks to fill that gap.\n\nThe goal of this clinical trial is to compare the effectiveness and safety of APC and EMR for treating gastric adenomas that are 1 cm or smaller with low-grade dysplasia. Specifically, the study aims to determine whether APC is \"non-inferior\" to EMR in preventing local recurrence of these lesions. In other words, researchers want to know if APC works just as well as EMR in controlling the disease, while also offering potential advantages such as fewer complications, shorter procedure time, and lower costs.\n\nParticipants in this study will:\n\nBe adults (age 20 or older) diagnosed with a gastric adenoma 1 cm or smaller with low-grade dysplasia.\n\nBe randomly assigned (by chance, like flipping a coin) to receive either APC or EMR.\n\nReceive standard medical care after the procedure, including medications to help the stomach heal.\n\nReturn for follow-up endoscopy at 3 months and 12 months after the procedure. During these visits, the treated area will be checked carefully, and biopsies may be taken to determine whether the lesion has recurred.\n\nProvide information about any complications, the duration of the procedure, and their recovery experience.\n\nThe main question is whether APC can prevent recurrence of gastric adenomas as effectively as EMR. Secondary questions include how the two treatments differ in terms of complications (such as bleeding or perforation) and procedure time.\n\nBoth APC and EMR are already established and commonly used treatments for gastric lesions. By directly comparing these two methods in a randomized controlled trial, this study will provide important evidence to guide future recommendations for patients with small gastric adenomas. The findings may help physicians and patients choose the best treatment option, balancing safety, effectiveness, and convenience.",[63,64,27,65],"Gastric Adenoma","Stomach Neoplasms","Dysplasia Stomach",[67,68,69,70,71,72,73,74,75],"Gastric adenoma","Low-grade dysplasia","Precancerous gastric lesion","Argon plasma coagulation (APC)","Endoscopic mucosal resection (EMR)","Endoscopic therapy","Local recurrence","Randomized controlled trial","Stomach neoplasms","RECRUITING","2026-02-04",{"date":79,"type":39},"2026-02-06",{"date":81,"type":39},"2026-01-20",{"date":83,"type":21},"2026-10",{"name":85,"class":46},"Samsung Medical Center",3,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":58,"phases":96,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100604507","phase-2-nebulized-inhalation-of-recombinant-human-p53-adenovirus-injection-for-treatment-of-multiple-ground-glass-lung-nodules-a-single-arm-clinical-study-100604507","NCT07150416","Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study","A Single-Arm Clinical Study of Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection (Gendicine) for Treatment of Multiple Ground-Glass Lung Nodules","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. CT scan confirms the presence of multiple ground-glass nodules (GGNs), with at least one nodule measuring between 0.5 cm and 3.0 cm in diameter.\n3. At least one GGN is confirmed as malignant or precancerous (e.g., atypical adenomatous hyperplasia, adenocarcinoma in situ) by histopathology or cytology.\n4. Life expectancy ≥ 12 weeks.\n5. Adequate pulmonary function tests (FEV1 ≥ 70% of predicted value).\n6. Signed informed consent.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of other active malignancies within the past 5 years.\n3. Severe cardiac, hepatic, or renal dysfunction (e.g., NYHA class III\u002FIV heart failure, ALT\u002FAST \\> 3×ULN, Cr \\> 1.5×ULN).\n4. Uncontrolled systemic infection or immunodeficiency diseases.\n5. Participation in another interventional clinical trial within 4 weeks prior to enrollment.\n6. Known hypersensitivity to any component of the recombinant human p53 adenovirus injection.",{"count":95,"type":21},38,[97],"PHASE2","This study aims to evaluate the safety and efficacy of nebulized inhalation of Recombinant Human Ad-p53 Injection (Gendicine®) for the treatment of multiple ground-glass lung nodules. This is a single-arm, open-label clinical study conducted at The First Affiliated Hospital of Guangzhou Medical University in China. We plan to enroll approximately 38 patients who have been diagnosed with multiple ground-glass nodules. All participants in this study will receive the nebulized Gendicine® treatment. After the treatment, we will monitor changes in the nodules through regular chest CT scans and record any potential treatment-related reactions to determine if this novel therapy is safe and effective. This study has been approved by the hospital's Ethics Committee.",[100,101,27],"Multiple Pulmonary Ground-Glass Nodules","Lung Neoplasms",[103,104,105,106],"p53 gene therapy","nebulized inhalation","Gendicine","Single-Arm Trial","2025-08-25",{"date":109,"type":39},"2025-09-02",{"date":111,"type":21},"2025-10-01",{"date":113,"type":21},"2027-02-01",{"name":115,"class":46},"The First Affiliated Hospital of Guangzhou Medical University",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":124,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":127,"studyType":23,"phases":4,"briefSummary":128,"conditions":129,"keywords":146,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":5},"100579293","raman-spectroscopy-based-deep-learning-model-for-early-pan-cancer-early-diagnosis-100579293","NCT06822413","Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","A Novel Raman Spectroscopy-Based Method for Pan-Cancers Early Diagnosis Supported by Deep Learning: A Prospective, Single-Arm, Multicentre Study","Inclusion Criteria:\n\n* Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.\n* Patients in normal physiological conditions without any malignant tumors or precancerous lesions.\n* Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.\n* Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.\n\nExclusion Criteria:\n\n* Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time\n* Post-cancer treatment patients.",true,{"count":126,"type":21},600,"1 Year","The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are:\n\n* Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk.\n* Identifying which model is more adaptable to the Raman spectrum\n* Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.",[130,131,132,133,134,135,136,137,138,139,140,27,141,142,143,144,145],"Cancer Diagnosis","Liver Cancer, Adult","Cancer Screening","Colorectal Cancer (CRC)","Gastric Cancers","Normal Physiology","Pancreatic Cancer, Adult","Raman Spectroscopy","Deep Learning Model","Esophageal Cancer","Malignant Tumours","Pancreatitis","Adenoma Colon Polyp","Gastric Ulcer","Oesophagitis","Cirrhoses, Liver",[147,148,132,137,149,150,151,139,152,153,141,154,155,144,156],"Pan-cancer","Deep Learning Models","Colorectal Cancer","Pancreatic Cancer","Gastric Cancer","malignant tumour","Precancerous Condtions","Colorectal Adenoma","Gastirc Ulcer","Cirrhoses","2025-04-19",{"date":159,"type":39},"2025-04-24",{"date":161,"type":39},"2022-09-01",{"date":163,"type":21},"2025-07-28",{"name":165,"class":46},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]